Compare ADPT & ROG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ADPT | ROG |
|---|---|---|
| Founded | 2009 | 1832 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Industrial Machinery/Components |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.6B |
| IPO Year | 2019 | 1994 |
| Metric | ADPT | ROG |
|---|---|---|
| Price | $24.81 | $133.98 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 1 |
| Target Price | $17.78 | ★ $133.00 |
| AVG Volume (30 Days) | ★ 2.7M | 237.0K |
| Earning Date | 05-05-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 63.89 | N/A |
| EPS | N/A | ★ 0.25 |
| Revenue | $276,976,000.00 | ★ $879,091,000.00 |
| Revenue This Year | $3.98 | $7.64 |
| Revenue Next Year | $22.72 | $6.09 |
| P/E Ratio | ★ N/A | $534.92 |
| Revenue Growth | ★ 54.77 | 7.07 |
| 52 Week Low | $11.93 | $69.61 |
| 52 Week High | $24.96 | $169.00 |
| Indicator | ADPT | ROG |
|---|---|---|
| Relative Strength Index (RSI) | 58.80 | 49.79 |
| Support Level | $15.08 | $130.83 |
| Resistance Level | N/A | $144.46 |
| Average True Range (ATR) | 1.38 | 6.07 |
| MACD | -0.01 | 1.02 |
| Stochastic Oscillator | 66.50 | 81.42 |
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.
Rogers Corp designs develop and manufactures engineered materials and components for sale to original equipment manufacturers and component suppliers. The firm operates in three business segments: Advanced Electronics Solutions, which manufactures circuit materials for applications in communications infrastructure, automotive, and consumer electronics markets; elastomeric material solutions, which provide cushioning, sealing, and impact protection in automotive, transportation, and construction applications; and Other, which consists of elastomer components for applications in the general industrial market, as well as elastomer floats for level sensing in fuel tanks, motors, and storage tanks applications in the general industrial and automotive markets.